STAA

STAAR is a high-quality, single-product franchise — ~100% of FY2026 sales are its proprietary Collamer ICLs, and the 76.2% gross margin proves the core economics are intact. The balance sheet is a genuine cushion: $153M cash (up 6.2% YoY), liabilities/equity of just 0.31x, and $312M current assets against $68.5M current liabilities. The franchise and the moat are not the problem.

The fundamentals, however, are deteriorating sharply. Revenue fell 23.7% to $239M — fully unwinding the FY2023 peak of $322M back to FY2021 levels — and the company swung to a -$80.4M net loss (-$1.62 diluted EPS), a -38.3% operating margin, and -$34.2M of operating cash burn. The accumulated deficit is now -$148M. Some of the loss is non-recurring (MD&A cites $17.1M of Alcon merger fees plus ~$7.0M reimbursed to Broadwood), so the 'true' loss is smaller, but even adjusted the business is unprofitable because the revenue decline has destroyed its operating leverage on a high-fixed-cost manufacturing base. The driver is concentration risk made real: China distributors are ~32% of sales, billed in USD, and a strong dollar plus soft Chinese demand is throttling the top line — the single most important variable here and one management can only partly offset with payment-term concessions.